Keros Therapeutics, Inc. (NASDAQ: KROS) is making waves in the biotechnology sector with its promising pipeline and recent analyst ratings suggesting a substantial growth potential. With a current market capitalization of $506.04 million, this US-based clinical-stage biopharmaceutical company is dedicated to developing novel therapeutics targeting disorders associated with dysfunctional signaling of the transforming growth factor-beta family of proteins.

At a current share price of $16.61, Keros is trading near the lower end of its 52-week range of $9.55 to $21.84. This positioning presents an intriguing opportunity for investors, especially with analysts projecting an average target price of $22.88, indicating a noteworthy…